<DOC>
	<DOCNO>NCT01956890</DOCNO>
	<brief_summary>This prospective study aim evaluate diagnostic effectiveness 18F-FLT PET differentiate benign nature malignancy lesion suspicious ambiguous finding mammography ultrasound ; determine whether 18F-FLT PET MRI increase specificity breast lesion diagnosis thus reduce unnecessary biopsy , ( 18F-FLT PET MRI ) reveal high diagnostic performance .</brief_summary>
	<brief_title>18F-FLT Positron Emission Tomography Magnetic Resonance Imaging Breast</brief_title>
	<detailed_description>It report PET ( Positron Emission Tomography ) scan also useful diagnose breast cancer . 18F-fluorodeoxyglucose ( 18F-FDG ) , base glucose metabolism determination malignancy , popular PET tracer present . However , 18F-FDG tumor specific . Benign inflammatory lesion may also demonstrate increase 18F-FDG uptake . On hand , low grade malignancy may low 18F-FDG concentration . Recently , 18F-3'-fluoro-3'-deoxy-L-thymidine ( 18F-FLT ) , radiolabelled analog thymidine , use image cell proliferation monitor treatment effect breast cancer patient . 18F-FLT believe specific 18F-FDG breast cancer diagnosis may provide underlined physiological molecular manifestation breast lesion addition anatomical manifestation mammography , ultrasound MRI . Yet , potential role differentiation ambiguous suspicious lesion find conventional imaging , like mammography ultrasound , report . We ongoing preliminary study regard breast lesion diagnosis use 18F-FLT PET , overall sensitivity 100 % specificity 92.7 % dataset ( 2010 August 2010 December , 19 lesion 8 woman correlation biopsy clinical outcome ) . On hand , molecular subtypes breast cancer , include ER ( Estrogen receptor ) , PR ( Progesterone receptor ) , HER2 ( Human epidermal growth factor receptor 2 ) associate treatment plan prediction clinical outcome breast cancer . There documented report regard relation mammography , DCE MRI , 18F-FDG PET ER , PR , HER2 status breast cancer . But association proton MRS , DWI 18F-FLT PET ER , PR , HER2 status seldom report .</detailed_description>
	<mesh_term>Alovudine</mesh_term>
	<criteria>1 ) Women age 20 80 year 2 ) woman localize finding mammography / ultrasound receive biopsy 3 ) The lesion conventional imaging measure &gt; =1cm 4 ) WBC count &gt; =3000/L , platelet &gt; =75,000/L 5 ) Liver function , AST ALT &lt; 78 U/L 6 ) Renal function , Creatinine &lt; 2.0 mg/dl. , estimate GFR ( eGFR ) &gt; 60ml/min/1.73m2 . 1 ) Pregnant woman plan pregnant , lactate . ( Eligible woman premenopausal reproductive potential receive urine pregnancy test MRI PET . Women positive pregnancy test exclude study . ) 2 ) Known cancer organ . 3 ) Women able cooperate PET/CT examination , MRI examination . 4 ) Women≦19 year old . 5 ) Past history severe anaphylactoid reaction MRIcontrast agent 18FFLT . 6 ) History mechanical valve replacement , recent coronary artery stent placement , pacemaker , aneurysmal clip , metallic endotracheal tube , procedures metallic device application . 7 ) eGFR≦60ml/min/1.73m2 . 8 ) History acute renal failure , renal dialysis .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Breast neoplasm</keyword>
	<keyword>PET</keyword>
	<keyword>MRI</keyword>
</DOC>